Certara Inc is expected to report Q2 2026 consensus revenue of $98.09 million and adjusted EPS of $0.10, with the stock currently trading at $8.09 against an average analyst price target of $8.12.
Investors are primarily focused on the financial impact of the company's recent $85 million divestiture of its Regulatory and Medical Writing business and the progress of its AI-driven biosimulation partnership with NVIDIA.
Recent performance has been pressured by softness in the services segment, which saw a 4% decline in the previous quarter, leading to a downward revision of full-year guidance. Analysts are looking for signs of margin expansion and growth recovery in core biosimulation software as the business mix shifts toward higher-value technology solutions.